The FDA on May 25, 2022, approved TIBSOVO® (Ivosidenib) in combination with Azacitidine (Azacitidine for injection) for newly diagnosed Acute Myeloid Leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. TIBSOVO® is a product of Servier Pharmaceuticals LLC.
Other Pages – Bottom Ad
Advertisement
Subscribe
